FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)
Second clinical program entering Phase 2 with data expected 2026BRISBANE, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Tempest ...
Tempest Therapeutics received ‘Study May Proceed’ letter from FDA on TPST-1495
Tempest Therapeutics (TPST) announced that the Cancer Prevention Clinical Trials Network received a “Study May Proceed” letter from the U.S.
Medicare To Reimburse Guardant Health's Shield Colorectal Cancer Test, Analyst Expects $10M In Revenue
CMS approves ADLT status for Guardant Health's Shield test, setting Medicare reimbursement at $1,495. The analyst sees a ...
Nasdaq5d
Tempest Therapeutics Receives FDA Approval to Advance Phase 2 Trial of TPST-1495 for Familial Adenomatous Polyposis
Tempest Therapeutics, Inc. has announced that the U.S. FDA has granted a "Study May Proceed" letter for their Phase 2 clinical trial of TPST-1495, a novel dual receptor inhibitor aimed at treating ...
Morningstar11d
Listed Index Fund Asian REIT
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Sigma Planning Corp Sells 1,495 Shares of Snowflake Inc. (NYSE:SNOW)
Sigma Planning Corp cut its stake in shares of Snowflake Inc. (NYSE:SNOW – Free Report) by 42.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,992 ...